WEKO3
アイテム
{"_buckets": {"deposit": "1fd03a7c-4c1a-494e-9476-a8ccda81d45c"}, "_deposit": {"created_by": 11, "id": "3636", "owners": [11], "pid": {"revision_id": 0, "type": "depid", "value": "3636"}, "status": "published"}, "_oai": {"id": "oai:shiga-med.repo.nii.ac.jp:00003636", "sets": ["79", "205", "228", "286"]}, "author_link": ["696", "6103", "844", "675", "644", "4010", "7507", "674", "7156", "2854", "677"], "item_4_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "139", "bibliographicPageStart": "129", "bibliographicVolumeNumber": "86", "bibliographic_titles": [{}, {"bibliographic_title": "Cancer chemotherapy and pharmacology", "bibliographic_titleLang": "en"}]}]}, "item_4_creator_3": {"attribute_name": "著者別名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "野田, 哲史"}], "nameIdentifiers": [{"nameIdentifier": "674", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60865707", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60865707"}]}, {"creatorNames": [{"creatorName": "平, 大樹"}], "nameIdentifiers": [{"nameIdentifier": "677", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50636959", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50636959"}, {"nameIdentifier": "0000-0001-8344-2469", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0001-8344-2469"}]}, {"creatorNames": [{"creatorName": "大崎, 理英"}], "nameIdentifiers": [{"nameIdentifier": "2854", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40737665", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=40737665"}]}, {"creatorNames": [{"creatorName": "藤本, 剛英"}], "nameIdentifiers": [{"nameIdentifier": "6103", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90792820", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=90792820"}]}, {"creatorNames": [{"creatorName": "飯田, 洋也"}], "nameIdentifiers": [{"nameIdentifier": "844", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30733901", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=30733901"}, {"nameIdentifier": "0000-0001-6245-4583", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0001-6245-4583"}]}, {"creatorNames": [{"creatorName": "田中, 佐智子"}], "nameIdentifiers": [{"nameIdentifier": "7507", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50453824", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50453824"}]}, {"creatorNames": [{"creatorName": "安藤, 朗"}], "nameIdentifiers": [{"nameIdentifier": "644", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90252395", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=90252395"}, {"nameIdentifier": "0000-0001-8533-2669", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0001-8533-2669"}]}, {"creatorNames": [{"creatorName": "谷, 眞至"}], "nameIdentifiers": [{"nameIdentifier": "696", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60236677", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60236677"}, {"nameIdentifier": "0000-0003-1270-6003", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0003-1270-6003"}]}, {"creatorNames": [{"creatorName": "池田, 義人"}], "nameIdentifiers": [{"nameIdentifier": "7156", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40736980", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=40736980"}]}, {"creatorNames": [{"creatorName": "森田, 真也"}], "nameIdentifiers": [{"nameIdentifier": "4010", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "20449870", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=20449870"}, {"nameIdentifier": "0000-0003-4079-707X", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0003-4079-707X"}]}, {"creatorNames": [{"creatorName": "寺田, 智祐"}], "nameIdentifiers": [{"nameIdentifier": "675", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10324641", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=10324641"}]}]}, "item_4_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose:\nSevere adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharmacokinetics of sorafenib in patients with hepatocellular carcinoma (HCC). ", "subitem_description_type": "Abstract"}, {"subitem_description": "Methods:\nThis was a retrospective, observational study in which 26 HCC patients who had been treated with sorafenib were enrolled between September 2010 and March 2015. The association between trough sorafenib concentration and occurrence of grade ≥ 3 toxicities was evaluated. In addition, we estimated the association of trough sorafenib concentration with overall survival (OS).", "subitem_description_type": "Abstract"}, {"subitem_description": "Results:\nThe median sorafenib concentration was 2.91 μg/mL (range 0.74-8.8 μg/mL). Based on the receiver operating characteristic curve, the threshold value of the trough sorafenib concentration for predicting grade ≥ 3 toxicities and responder (complete response or partial response at best response, or stable disease for ≥ 3 months) was 3.45 μg/mL [area under the curve (AUC) 0.74, 95% confidence interval (CI) 0.54-0.93; p \u003c0.05] and 1.40 μg/mL (AUC 0.97, 95% CI 0.97-1.00; p \u003c0.05), respectively. OS of patients with sorafenib 1.40-3.45 µg/mL had a tendency to be longer than those of patients administered \u003c 1.40 μg/mL and ≥ 3.45 μg/mL [median 17.8 months (1.40-3.45 μg/mL) vs. 5.3 months (\u003c 1.40 μg/mL) and 9.5 months (≥ 3.45 μg/mL)]. ", "subitem_description_type": "Abstract"}, {"subitem_description": "Conclusions:\nFrom results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40-3.45 μg/mL in patients with HCC. ", "subitem_description_type": "Abstract"}]}, "item_4_description_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Journal Article", "subitem_description_type": "Other"}]}, "item_4_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer Nature"}]}, "item_4_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "32588123", "subitem_relation_type_select": "PMID"}}]}, "item_4_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1007/s00280-020-04105-0"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1007/s00280-020-04105-0", "subitem_relation_type_select": "DOI"}}]}, "item_4_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© Springer-Verlag GmbH Germany, part of Springer Nature 2020"}]}, "item_4_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1432-0843", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "NODA, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "674", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60865707", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60865707"}]}, {"creatorNames": [{"creatorName": "HIRA, Daiki"}], "nameIdentifiers": [{"nameIdentifier": "677", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50636959", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50636959"}, {"nameIdentifier": "0000-0001-8344-2469", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0001-8344-2469"}]}, {"creatorNames": [{"creatorName": "OSAKI, Rie"}], "nameIdentifiers": [{"nameIdentifier": "2854", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40737665", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=40737665"}]}, {"creatorNames": [{"creatorName": "FUJIMOTO, Takehide"}], "nameIdentifiers": [{"nameIdentifier": "6103", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90792820", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=90792820"}]}, {"creatorNames": [{"creatorName": "IIDA, Hiroya"}], "nameIdentifiers": [{"nameIdentifier": "844", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30733901", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=30733901"}, {"nameIdentifier": "0000-0001-6245-4583", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0001-6245-4583"}]}, {"creatorNames": [{"creatorName": "Tanaka-Mizuno, Sachiko"}], "nameIdentifiers": [{"nameIdentifier": "7507", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50453824", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50453824"}]}, {"creatorNames": [{"creatorName": "ANDOH, Akira"}], "nameIdentifiers": [{"nameIdentifier": "644", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90252395", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=90252395"}, {"nameIdentifier": "0000-0001-8533-2669", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0001-8533-2669"}]}, {"creatorNames": [{"creatorName": "TANI, Masaji"}], "nameIdentifiers": [{"nameIdentifier": "696", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60236677", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60236677"}, {"nameIdentifier": "0000-0003-1270-6003", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0003-1270-6003"}]}, {"creatorNames": [{"creatorName": "IKEDA, Yoshito"}], "nameIdentifiers": [{"nameIdentifier": "7156", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40736980", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=40736980"}]}, {"creatorNames": [{"creatorName": "MORITA, Shin-ya"}], "nameIdentifiers": [{"nameIdentifier": "4010", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "20449870", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=20449870"}, {"nameIdentifier": "0000-0003-4079-707X", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0003-4079-707X"}]}, {"creatorNames": [{"creatorName": "TERADA, Tomohiro"}], "nameIdentifiers": [{"nameIdentifier": "675", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10324641", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=10324641"}]}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Hepatocellular carcinoma", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Personalized pharmacotherapy", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Pharmacokinetics", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Sorafenib", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study."}]}, "item_type_id": "4", "owner": "11", "path": ["79", "205", "228", "286"], "permalink_uri": "http://hdl.handle.net/10422/00012754", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-07-08"}, "publish_date": "2020-07-08", "publish_status": "0", "recid": "3636", "relation": {}, "relation_version_is_last": true, "title": ["Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study."], "weko_shared_id": -1}
Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study.
http://hdl.handle.net/10422/00012754
http://hdl.handle.net/10422/0001275477df3014-4749-48d7-93f7-cf6d35274e5a
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-07-08 | |||||
タイトル | ||||||
タイトル | Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Hepatocellular carcinoma | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Personalized pharmacotherapy | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Pharmacokinetics | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Sorafenib | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
NODA, Satoshi
× NODA, Satoshi× HIRA, Daiki× OSAKI, Rie× FUJIMOTO, Takehide× IIDA, Hiroya× Tanaka-Mizuno, Sachiko× ANDOH, Akira× TANI, Masaji× IKEDA, Yoshito× MORITA, Shin-ya× TERADA, Tomohiro |
|||||
著者別名 |
野田, 哲史
× 野田, 哲史× 平, 大樹× 大崎, 理英× 藤本, 剛英× 飯田, 洋也× 田中, 佐智子× 安藤, 朗× 谷, 眞至× 池田, 義人× 森田, 真也× 寺田, 智祐 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose: Severe adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharmacokinetics of sorafenib in patients with hepatocellular carcinoma (HCC). |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Methods: This was a retrospective, observational study in which 26 HCC patients who had been treated with sorafenib were enrolled between September 2010 and March 2015. The association between trough sorafenib concentration and occurrence of grade ≥ 3 toxicities was evaluated. In addition, we estimated the association of trough sorafenib concentration with overall survival (OS). |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Results: The median sorafenib concentration was 2.91 μg/mL (range 0.74-8.8 μg/mL). Based on the receiver operating characteristic curve, the threshold value of the trough sorafenib concentration for predicting grade ≥ 3 toxicities and responder (complete response or partial response at best response, or stable disease for ≥ 3 months) was 3.45 μg/mL [area under the curve (AUC) 0.74, 95% confidence interval (CI) 0.54-0.93; p <0.05] and 1.40 μg/mL (AUC 0.97, 95% CI 0.97-1.00; p <0.05), respectively. OS of patients with sorafenib 1.40-3.45 µg/mL had a tendency to be longer than those of patients administered < 1.40 μg/mL and ≥ 3.45 μg/mL [median 17.8 months (1.40-3.45 μg/mL) vs. 5.3 months (< 1.40 μg/mL) and 9.5 months (≥ 3.45 μg/mL)]. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Conclusions: From results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40-3.45 μg/mL in patients with HCC. |
|||||
書誌情報 |
en : Cancer chemotherapy and pharmacology 巻 86, 号 1, p. 129-139, 発行日 2020-07 |
|||||
出版者 | ||||||
出版者 | Springer Nature | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1432-0843 | |||||
PMID | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 32588123 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1007/s00280-020-04105-0 | |||||
関連名称 | 10.1007/s00280-020-04105-0 | |||||
権利 | ||||||
権利情報 | © Springer-Verlag GmbH Germany, part of Springer Nature 2020 | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal Article |